The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, it said.
The new patents are valid through 2034. It was not clear whether the compound has been granted patents in any other country prior to this.
““We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
Suven Life Sciences focuses on discovering, developing and commercializing new pharmaceutical products.
It has 4 clinical stage compounds — SUVN-502 undergoing a Phase 2 studies, SUVN-G3031 ready for Phase 2, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.
“In addition to these clinical compounds the Company has nine internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain,” it said.